Overview of Key Investments

Combating the Global Threat Jeopardizing Modern Medicine

AR Solutions Initiative Overview[PDF - 2 pages]

CDC's strategic investments empower the nation to combat AR, the global threat jeopardizing modern medicine. These investments work toward meeting national goals to prevent drug-resistant infections as outlined in the National Action Plan for Combating Antibiotic-Resistant Bacteria.

Learn how CDC is investing in your area to combat AR: Use the Antibiotic Resistance Investment Map for information on CDC’s key AR activities by state.

With these investments, the CDC, in partnership with health departments, academia, and healthcare, is transforming how the nation combats and slows antibiotic resistance at all levels, ensuring our ability to stand up a full, faster response to protect Americans from this threat. These investments will better protect patients through:

Detection and Response

Rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread
Gold-standard lab capacity offered to all state and regional labs through CDC’s Antibiotic Resistance Laboratory Network
Expanded overseas tuberculosis (TB) screenings and a national drug stockpile to prevent shortages of medicine needed to treat TB.

Prevention of Infections

Improve prevention of healthcare-associated infections, foodborne illness, and gonorrhea
Empowered networks for prevention across healthcare and communities for threats like Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), and “nightmare bacteria” carbapenem-resistant Enterobacteriaceae (CRE)
Insights for research innovation and better patient care

Improving Antibiotic Use

Ensure antibiotics work to protect patients from life-threatening infections or sepsis
Protect patients from unintended consequences associated with antibiotic use, including adverse drug events

View CDC’s fact sheets by topic for more information on how AR Solutions Initiative activities provide critical support to combat antibiotic-resistant bacteria.